Credit: SartoriusSartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this year’s CYTO® conference and exhibition, with the launch of the Intellicyt iQue3. The event–which takes place in Vancouver, Canada, from June 22 to 26–will give delegates the chance to explore a smarter way to perform flow cytometry experiments.
The iQue3 is designed to provide fully automated processing and analysis for flow cytometry workflows, taking you from samples to actionable answers faster than ever before. Successor to the iQue Screener PLUS, the new generation instrument offers even more user-friendly operation and enhanced process security to ensure consistent and reliable results with minimal user intervention.
One of the iQue3’s new features is an enhanced rinse station that actively monitors buffer usage. With built-in liquid level detection, this module offers a smarter way to ensure you always have sufficient buffers to complete your run. This is complemented by a number of updates to the system’s intuitive ForeCyt software, which uses a unique templated analysis approach to offer intelligent, fully automated data processing. This powerful software solution has been specifically developed to alleviate common processing bottlenecks by eliminating the need for manual data analysis and providing real-time visualization of your data for virtually any cell- or bead-based assay.
To learn how to get from samples to actionable results in hours not days, go to www.sartorius.com/intellicyt or visit booth #103 at CYTO 2019.
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, Sartorius earned sales revenue of around 1.57 billion euros. Currently, some 8,500 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe. Visit www.sartorius.com/intellicyt
Like this article? Click here to subscribe to free newsletters from Lab Manager